Burlingame, CA, United States of America

Timothy Heffron

USPTO Granted Patents = 28 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 14 (Patent Applications = 16)

Average Co-Inventor Count = 12.5

ph-index = 6

Forward Citations = 215(Granted Patents)

Location History:

South San Francisco, CA (US) (2012 - 2014)
Burlingame, CA (US) (2013 - 2024)

Company Filing History:

F. Hoffmann-la Roche Ag

Years Active: 2012-2025

Loading Chart...

28 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

2. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

3. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

4. 12208088 - Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof (2025-01-28),

5. 11944606 - Azaindoles as inhibitors of HPK1 (2024-04-02),

6. 11612606 - 8-aminoisoquinoline compounds and uses thereof (2023-03-28),

7. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

8. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

9. 10952995 - Azaindoles as inhibitors of HPK1 (2021-03-23),

10. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

11. 9951064 - Azaindazole compounds as inhibitors of T790M containing EGFR mutants (2018-04-24),

12. 9890152 - Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants (2018-02-13),

13. 9670228 - Benzoxazepin PI3K inhibitor compounds and methods of use (2017-06-06),

14. 9546182 - Tricyclic PI3K inhibitor compounds and methods of use (2017-01-17),

15. 9546178 - Benzoxazepin PI3K inhibitor compounds and methods of use (2017-01-17),

Title: Timothy Heffron: Pioneering Innovations in Biomedical Research

Introduction:

Timothy Heffron is a prolific inventor based in Burlingame, CA, with a remarkable portfolio of 24 patents to his name. His groundbreaking work in developing novel compounds for treating HPK1-dependent disorders has revolutionized the field of biomedical research.

Latest Patents:

Heffron's latest patents showcase his cutting-edge approach to combating HPK1-dependent disorders. The first patent involves Azaindole compounds that serve as potent inhibitors of HPK1, offering new avenues for treating such disorders and boosting immune responses. The second patent focuses on 3-Carbonylamino-8-aminoisoquinoline compounds, which also demonstrate significant potential in inhibiting HPK1 and enhancing immune responses.

Career Highlights:

With a career spanning years of dedication to research and innovation, Heffron has left an indelible mark on the pharmaceutical industry. He has contributed significantly to companies like Genentech, Inc., and F. Hoffmann-La Roche AG, where his expertise has been instrumental in developing cutting-edge pharmaceutical solutions.

Collaborations:

Throughout his career, Heffron has collaborated closely with esteemed professionals in the field. Notable coworkers include Robert Andrew Heald and Alan G Olivero, with whom he has worked synergistically to drive forward groundbreaking research projects and secure patents for revolutionary inventions.

Conclusion:

In conclusion, Timothy Heffron stands as a trailblazing figure in the realm of biomedical innovation. His relentless pursuit of novel solutions for HPK1-dependent disorders has paved the way for advancements in healthcare and immunology. Heffron's contributions continue to inspire and shape the landscape of biomedical research, making him a true visionary in the field.

This text is generated by artificial intelligence and may not be accurate.